AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01350622
Drug: Diclofenac hydroxyethylpyrrolidine
RxNorm normalized name: diclofenac hydroxyethylpyrrolidine 1.292 % Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: active treatment oral Diclofenac and PENNSAID placebo. Patients will take a single 50mg dose of oral diclofenac and will apply 40 drops of placebo lotion (2.3% DMSO) to the affected ankle once.
Trial: NCT03435302
Drug: High-Dose IFN-a2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon belongs to the large class of glycoproteins known as cytokines.
Trial: NCT01593787
Drug: LCZ696
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg, 200 mg, 400 mg tablets.
Trial: NCT02644278
Drug: VX-984 240 mg + PLD 40 mg/m^2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received VX-984 orally 240 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 240 mg in combination with PLD 40 mg/m\^2 administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m\^2.
Trial: NCT03993262
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 to 3 cycles placebo (NaCl solution) s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)
Trial: NCT03468478
Drug: Mycophenolic acid
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control arm: mycophenolate combined to regular tacrolimus
Trial: NCT02537210
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be prescribed placebo 5 capsules daily for 12 months
Trial: NCT03572647
Drug: Eritromax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will receive a single dose of 4000 IU epoetin alfa in each period, according to randomisation.
Trial: NCT03572647
Drug: Eprex
RxNorm normalized name: Eprex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will receive a single dose of 4000 IU epoetin alfa in each period, according to randomisation.
Trial: NCT03211234
Drug: 2.0 mg DE-122 Injectable Solution + Lucentis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive 6 monthly intravitreal injections of low dose DE-122 in the study eye, in combination with Lucentis.
Trial: NCT03418935
Drug: Remaxol (succinate + methionine + inosine + nicotinamide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for intravenous infusions, containing succinate, methionine, inosine, and nicotinamide in 400 ml glass bottle
Trial: NCT02666963
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03881059
Drug: BMS-986165 Dose B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive BMS-986165 dose B QD.
Trial: NCT00954889
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (tamsulosin 0.2mg + placebo)/day Posology: two tablet to be taken after an evening meal tamsulosin Tablet is an orally. (smoothly ingested without water)
Trial: NCT00449618
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of placebo on awakening versus bedtime
Trial: NCT01367288
Drug: Zometa + Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg (in a 15 min. infusion) every 3 weeks for a total of 8 injections
Trial: NCT01367288
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 injections of doxorubicin (60 mg/m²) combined with cyclophosphamide (600 mg/m²) every 3 weeks (+/- 2 days), followed by 4 injections of docetaxel (100 mg/m²) every 3 weeks (+/- 2 days)
Trial: NCT00114153
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02644278
Drug: VX-984 480 mg + PLD 40 mg/m^2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received VX-984 orally 480 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 480 mg in combination with PLD 40 mg/m\^2 administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m\^2.
Trial: NCT01666587
Drug: Prostaglandin inhibitor (Ibuprophen)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02185222
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study of superiority between Cholecalciferol high dose 100 000 UI versus placebo : one bulb per month during two years
Trial: NCT04180488
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Injection solution Route of administration: Subcutaneous
Trial: NCT02393300
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The normal saline solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
Trial: NCT00214916
Drug: intensive insulin therapy (Actrapid IV to normoglycemia)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intensive insulin therapy (Actrapid IV in continuous infusion to age-dependent normoglycemia)
Trial: NCT02961803
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02644278
Drug: VX-984 720 mg + PLD 40 mg/m^2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received VX-984 orally 720 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 720 mg in combination with PLD 40 mg/m\^2 administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m\^2.
Trial: NCT02025192
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m\^2 administered twice per day, orally in Days 1-14 of each 21-day cycle.
Trial: NCT02458781
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given twice daily for 14 days
Trial: NCT04488016
Drug: Treatment A- Part 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive 100 mg acalabrutinib capsule, fasted state;
Trial: NCT04488016
Drug: Treatment B- Part 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fasted state
Trial: NCT04488016
Drug: Treatment C - Part 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fed state
Trial: NCT04358965
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will be given one vaginal placebo tablet 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
Trial: NCT01566786
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose of trial drug 10 mcg/kg, escalating up to five dose tiers: 20 mcg/kg, 40 mcg/kg, 80 mcg/kg, 120 mcg/kg and 160 mcg/kg. Administered within the first 4 hours after the insult
Trial: NCT02562443
Drug: Any approved or standard-of-care therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive Physician's Choice of Treatment or alternative treatment which may include any approved or standard-of-care therapy, based on frequently used treatment for MDS (no experimental therapy) + best supportive care.
Trial: NCT02562443
Drug: best supportive care (BSC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive best supportive care (BSC): azacitidine (AZA) and/or decitabine (DAC) are permitted.
Trial: NCT02562443
Drug: best supportive care (BSC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive best supportive care (BSC).
Trial: NCT00513188
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00513188
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00513188
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00513188
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01228331
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: together wit MTX and ASP in consolidation and together with cytarabine and 6-TG in reinduction
Trial: NCT01228331
Drug: Doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: part of reinduction therapy
Trial: NCT01228331
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: part of different chemotherapy blocks
Trial: NCT01228331
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: part of different chemotherapy blocks
Trial: NCT01660386
Drug: Blank control
RxNorm normalized name: acid black 52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the subjects take no medication at experimental day and start bi-phase hyperglycaemic clamp at 9am.
Trial: NCT00789360
Drug: Inhaled Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Staccato Placebo, 2 inhalations, 8 hours apart
Trial: NCT03139604
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets administered orally once daily (QD) plus corticosteroids.
Trial: NCT00206388
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: fixed dose of 25mg/m2/dose days 0-27
Trial: NCT00142090
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline
Trial: NCT01454180
Drug: gemcitabine, or gemcitabine and capecitabine, or gemcitabine and erlotinib, or FOLFIRINOX, or FOLFOX, or FOLFIRI.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks.~* Gemcitabine - Capecitabine (GEM-CAP):Gemcitabine 1000 mg/m2 weekly for 3 weeks, Capecitabine 830 mg/m2 orally every 12 hours daily for 3 weeks; every 4 weeks.~* Gemcitabine-Erlotinib: Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks, Erlotinib 100 mg orally daily~* FOLFOXIRI: Oxaliplatin 85 mg/m2,irinotecan 180 mg/m2, folinic acid 400 mg/m2, 5'Fluouracilo 400 mg / m2, 5 'fluorouracil 2400 mg/m2 continuous intravenous infusion of 46 hours. Repeated every 14 days.~* FOLFOX: Oxaliplatin 85 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo, 2400 mg/m2 5'Fluouracilo continuous intravenous infusion of 46 hours. Repeated every 14 days.~* FOLFIRI: Irinotecan 180 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo intravenous bolus, 5'Fluouracilo 2400 mg / m2 continuous intravenous infusion for 46 hours. Repeated every 14 days.
Trial: NCT01454180
Drug: Gemcitabine, Gemcitabine-Capecitabine, Gemcitabine-Erlotinib, FOLFOXIRI, FOLFOX, FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks.~* Gemcitabine - Capecitabine (GEM-CAP):Gemcitabine 1000 mg/m2 weekly for 3 weeks, Capecitabine 830 mg/m2 orally every 12 hours daily for 3 weeks; every 4 weeks.~* Gemcitabine-Erlotinib: Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks, Erlotinib 100 mg orally daily~* FOLFOXIRI: Oxaliplatin 85 mg/m2,irinotecan 180 mg/m2, folinic acid 400 mg/m2, 5'Fluouracilo 400 mg / m2, 5 'fluorouracil 2400 mg/m2 continuous intravenous infusion of 46 hours. Repeated every 14 days.~* FOLFOX: Oxaliplatin 85 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo, 2400 mg/m2 5'Fluouracilo continuous intravenous infusion of 46 hours. Repeated every 14 days.~* FOLFIRI: Irinotecan 180 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo intravenous bolus, 5'Fluouracilo 2400 mg / m2 continuous intravenous infusion for 46 hours. Repeated every 14 days.
Trial: NCT02206477
Drug: Saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02383940
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, once daily before the first meal of the day
Trial: NCT03926195
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match filgotinib tablet administered orally once daily
Trial: NCT04374539
Drug: Standar medical treatmen
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kaletra: lopinavir/ritonavir: 2c/12h 7 days~* Hydroxychloroquine sulfate 400 mg/12h the first day followed by 200 mg /12h 4 days~* Azithromycin 500 mg first day, followed by 250 mg /d 4 days (oral or EV)~* Tocilizumab 400 mg (weight \<75Kgs) or 600 mg (weight ≥ 75 Kg)~* Methylprednisolone 250 mg EV three days and 30 mg/d another 3 days~* Anakinra 200mg/ 12h SBC first day, 200mg / 24h SBC two more days~* Clexane 40-60 mg/d
Trial: NCT02251769
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00564746
Drug: A single 10 milligram (50 microcurie) oral dose of [14C]SB-681323
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[14C\] SB-681323 oral solution, is available as a powder which will be made into a solution of 0.1 milligram/milliliter (0.5 microcurie) \[14C\] SB-681323 in dextrose and water for injection on the day prior to dosing.~For a 10 milligram/50 microcurie oral dose of \[14C\]SB-681323, 100 milliliters of 0.1 milligram/milliliter (0.5 microcurie/milliliter \[14C\] SB-681323 oral solution will be dosed.
Trial: NCT04297631
Drug: Tobramycin Powder
RxNorm normalized name: tobramycin Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everyone gets tobramycin powder.
Trial: NCT00469781
Drug: 2. Xibrom (Bromfenac)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 and 2: 1 drop(Instill one drop in the eye that was operated on twice daily)3 days prior to surgery and 4 doses during dilation immediately before the procedure. Use for 4 weeks after surgery.
Trial: NCT00203905
Drug: 5-Fluorouracil, Hydroxyurea-[FHX]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea at 500 mg PO q 12 hours x 6 days; Infusion of 5-FU (600 mg/m2/day) X 5 days (120 hours)
Trial: NCT01399697
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: orally, Week 1 - 16
Trial: NCT01399697
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: orally, Week 17-28
Trial: NCT01399697
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methotrexate placebo orally, Week 17-28
Trial: NCT02207491
Drug: AR-13324 Ophthalmic Solution 0.02%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop once daily (QD), PM, OU
Trial: NCT00277589
Drug: Levothyroxin-Na
RxNorm normalized name: Levothyroxine Sodium
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 tablet 30 minutes before breakfast
Trial: NCT00277589
Drug: Levothyroxine-Na + iodide
RxNorm normalized name: levothyroxine sodium / potassium iodide Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet 30 minutes before breakfast
Trial: NCT00277589
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet 30 minutes before breakfast
Trial: NCT02233803
Drug: NEUMOTEROL 400 (BFF 400/12 mcg) single capsule inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized 400 mcg budesonide+ 12 mcg formoterol fumarate along with micronized and crystalline lactose monohydrate (excipient), per capsule dispensed by single capsule inhaler, twice daily (administered once in the morning and once in the evening approximately 12 hours later).
Trial: NCT02233803
Drug: SYMBICORT forte (BFF 320/9mcg) TURBUHALER inhaler
RxNorm normalized name: Symbicort Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unit dose containing 320 mcg budesonide and 9 mcg formoterol fumarate (as dihidrate) along with lactose monohydrate as excipient. Administered as inhalation by TURBUHALER inhaler, twice daily (once in the morning and once in the evening approximately 12 hours later)
Trial: NCT02233803
Drug: NEUMOTEX 400 (Budesonide 400 mcg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 400mcg will be administered to all the subjects twice daily, during the Run-in and Washout Periods
Trial: NCT01745692
Drug: Intravenous rtPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients receive IV alteplase
Trial: NCT00006375
Drug: LY293111
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04224857
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single or daily dosing at doses A, B, C, D, E, F
Trial: NCT01661764
Drug: Eicosapentanoic acid and docosahexanoic acid
RxNorm normalized name: docosahexaenoic acid / eicosapentaenoic acid Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1395 mg EPA plus 1125 mg DHA daily for 24 weeks
Trial: NCT02922673
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02268825
Drug: MK-3475
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-3475 in combination with mFOLFOX6 in a 14 day cycle~Phase 1 and safety expansion Phased Regimen mFOLFOX6 Administered Day 1 of each cycle Leucovorin 400 mg/m2 IV 5-FU 400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hrs Oxaliplatin (Eloxatin) 85 mg/m2 IV~MK-3475 IV to be administered before mFOLFOX6 starting with Cycle 3 (after 28 days of chemotherapy alone); day 1 of each cycle (q 2 weeks)~Phase 1: 2 dose levels of MK-3475 Level -1: 50mg IV q 2 weeks Level 1: 75mg IV q 2 weeks Level 2: 200mg IV q 2 weeks~Safety Expansion: MK-3475 at highest tolerated dose
Trial: NCT03183505
Drug: Anyu Peibo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anyu Peibo Capsule, 0.8g twice per day, oral after breakfast and supper
Trial: NCT03183505
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Capsule, twice per day, oral after breakfast and supper
Trial: NCT01383655
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl
Trial: NCT00539305
Drug: testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50-100mg applied topically daily for six months
Trial: NCT00539305
Drug: placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: applied topically daily for six months
Trial: NCT02601586
Drug: Levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa
Trial: NCT01404429
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Different doses for both arms followed by similar escalation (2.5 mg every 15 d) till max of 25 mg per week or 3 months completed
Trial: NCT03653208
Drug: hzVSF-v13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form: 10mg / 20mg / 50mg / 100mg / 200mg / 400mg / 800mg / 1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1 (single administration)
Trial: NCT03653208
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form: 0.9% NaCl Solution Frequency: Dose at Day 1 (single administration)
Trial: NCT01363908
Drug: SPD602
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02601586
Drug: Levodopa placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04016051
Drug: Clarithromycin DST (125 mg)
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin DST (125.0 mg clarithromycin / straw).
Trial: NCT04016051
Drug: Clarithromycin DST (187.5 mg)
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin DST (187.5 mg clarithromycin / straw).
Trial: NCT04016051
Drug: Clarithromycin DST (250 mg)
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin DST (250.0 mg clarithromycin / straw).
Trial: NCT04016051
Drug: Clarithromycin Syrup (125 mg)
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin Syrup 2.5 ml (125 mg).
Trial: NCT04016051
Drug: Clarithromycin Syrup (187.5 mg)
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin Syrup 3.75 ml (187.5 mg).
Trial: NCT04016051
Drug: Clarithromycin Syrup (250 mg)
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin Syrup 5 ml (250 mg).